Exane Derivatives I Mab Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in I Mab stock. As of the latest transaction made, Exane Derivatives holds 14 shares of IMAB stock, worth $28. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14
Previous 14
-0.0%
Holding current value
$28
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding IMAB
# of Institutions
39Shares Held
13.8MCall Options Held
20KPut Options Held
13.3K-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$12.1 Million0.15% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$8.46 Million3.04% of portfolio
-
Sg Americas Securities, LLC822KShares$1.67 Million0.0% of portfolio
-
Stonepine Capital Management, LLC Bend, OR484KShares$981,8030.39% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny363KShares$737,2950.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $169M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...